Neurosterix Company Profile

Background

Neurosterix is a biopharmaceutical company established in April 2024, dedicated to developing allosteric modulators for the treatment of neurological disorders. The company's mission is to provide innovative therapies that offer improved efficacy, safety, and tolerability for patients suffering from underserved neurological conditions. By focusing on allosteric modulation—a pharmacological approach that enhances or diminishes receptor activity by binding outside the traditional active site—Neurosterix aims to revolutionize treatments in the neurology sector.

Key Strategic Focus

Neurosterix's strategic focus centers on advancing a pipeline of allosteric modulators targeting specific neurological disorders. The company's core objectives include:

M4 Positive Allosteric Modulator (PAM): Aimed at treating schizophrenia and other psychoses, with Investigational New Drug (IND) enabling studies initiated in Q3 2024.

mGlu7 Negative Allosteric Modulator (NAM): Targeting mood disorders, with IND enabling studies scheduled to commence in the first half of 2025.

mGlu2 NAM: Focused on cognitive enhancement, entering clinical candidate selection in the first half of 2025.

Undisclosed Program: A central nervous system (CNS) project set to begin lead optimization in the first half of 2025.

These programs leverage Neurosterix's proprietary allosteric modulator drug discovery platform to address unmet needs in neurological therapeutics.

Financials and Funding

In April 2024, Neurosterix secured a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures. This funding facilitated the acquisition of a portfolio of preclinical neuroscience assets and the allosteric modulator drug discovery technology platform from Addex Therapeutics. In return, Addex received CHF 5 million and a 20% equity interest in Neurosterix.

Pipeline Development

Neurosterix's pipeline includes:

M4 PAM: Targeting schizophrenia and other psychoses, with IND enabling studies initiated in Q3 2024.

mGlu7 NAM: Aimed at mood disorders, with IND enabling studies planned for the first half of 2025.

mGlu2 NAM: Focused on cognitive enhancement, entering clinical candidate selection in the first half of 2025.

Undisclosed CNS Program: Set to begin lead optimization in the first half of 2025.

These programs are designed to address significant unmet needs in neurological therapeutics.

Technological Platform and Innovation

Neurosterix's proprietary allosteric modulator drug discovery platform is a cornerstone of its innovation strategy. This platform identifies and develops allosteric modulators—molecules that modulate receptor activity by binding outside the traditional active site. This approach offers greater selectivity and precision in controlling biological pathways, potentially leading to therapies with improved efficacy and safety profiles.

Leadership Team

Tim Dyer: Chief Executive Officer. Tim Dyer also serves as CEO of Addex Therapeutics and has been instrumental in the establishment and strategic direction of Neurosterix.

Fred Callori: Chairman of the Board. Managing Director, Venture at Perceptive Advisors, providing strategic oversight and guidance to Neurosterix.

Leadership Changes

Upon its launch, Neurosterix appointed Tim Dyer as CEO, concurrently holding the same position at Addex Therapeutics. Additionally, key members from Addex's research and development team transitioned to Neurosterix, including:

Robert Lutjens and Jean-Philippe Rocher: Appointed as Co-Heads of Discovery.

Mikhail Kalinichev: Assumed the role of Head of Translational Science.

These leadership changes were part of the strategic realignment following the acquisition of assets from Addex Therapeutics.

Competitor Profile

Market Insights and Dynamics

The global market for neurological disorder treatments is substantial, with significant growth potential driven by increasing prevalence and unmet medical needs. Advancements in drug discovery technologies, particularly in allosteric modulation, are poised to transform therapeutic approaches in this sector.

Competitor Analysis

Neurosterix operates in a competitive landscape with several key players:

Asceneuron: Focuses on developing small molecules targeting neurodegenerative diseases.

ZyVersa Therapeutics: Specializes in treatments for inflammatory and renal diseases, with a pipeline that includes neurological applications.

Pharma Two B: Develops combination therapies for Parkinson's disease.

Alzheon: Concentrates on therapies for Alzheimer's disease and other neurodegenerative disorders.

Cerecin: Focuses on developing treatments for neurological diseases using ketone-based therapies.

These companies represent the competitive environment in which Neurosterix operates, each contributing to advancements in neurological therapeutics.

Strategic Collaborations and Partnerships

Neurosterix was established through a strategic collaboration between Addex Therapeutics and Perceptive Advisors. This partnership involved the acquisition of Addex's allosteric modulator drug discovery platform and preclinical neuroscience assets, supported by a $63 million investment led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures.

Operational Insights

Neurosterix's competitive advantage lies in its proprietary allosteric modulator drug discovery platform, which enables the development of highly selective and efficacious therapies for neurological disorders. The company's strategic focus on underserved conditions positions it to address significant gaps in the current treatment landscape.

Strategic Opportunities and Future Directions

Looking ahead, Neurosterix aims to advance its pipeline candidates through clinical development, leveraging its robust discovery platform and strategic partnerships. The company's focus on allosteric modulation offers the potential to develop therapies with improved safety and efficacy profiles, addressing unmet needs in neurological disorders.